Skip to main content

Oxaliplatin

Type of Posting: Revision Bulletin

Posting Date: 28–May–2010

Official Date: 01–Jul–2010

Expert Committee: Monograph Development—Ophthalmology, Oncology, and Dermatology

In accordance with the Rules and Procedures of the 2005–2010 Council of Experts, the Monograph Development—Ophthalmology, Oncology, and Dermatology Expert Committee has revised the Oxaliplatin monograph. The purpose for the revision is to accommodate the sponsor's FDA-approved specifications for Limit of silver, Organic impurities, and Loss on Drying.

The Oxaliplatin Revision Bulletin supersedes the currently official monograph and will be incorporated in the USP 34–NF 29.

Should you have any questions, please contact Feiwen Mao (301-816-8320 or fm@usp.org).